Where is Gene Therapy Program | University of Pennsylvania's headquarters located?

Gene Therapy Program | University of Pennsylvania's main headquarters is located at 125 South 31st Street Philadelphia, Pennsylvania United States.

What is Gene Therapy Program | University of Pennsylvania's phone number?

You can contact Gene Therapy Program | University of Pennsylvania's main corporate office by phone at +1-215-573-****.

What is Gene Therapy Program | University of Pennsylvania's stock symbol?

Gene Therapy Program | University of Pennsylvania is a publicly traded company; the company's stock symbol is N/A.

What is Gene Therapy Program | University of Pennsylvania's official website and social media links?

Gene Therapy Program | University of Pennsylvania's official website is gtp.med.upenn.edu. Gene Therapy Program | University of Pennsylvania has social profiles on LinkedIn.

How many employees does Gene Therapy Program | University of Pennsylvania have currently?

Gene Therapy Program | University of Pennsylvania has approximately 28 employees.

What industry does Gene Therapy Program | University of Pennsylvania belong to?

Gene Therapy Program | University of Pennsylvania operates in the Biotechnology Research industry.

What technology does Gene Therapy Program | University of Pennsylvania use?

Gene Therapy Program | University of Pennsylvania's tech stack includes Yoast SEO Premium, HSTS, UPS, Vimeo, Google Cloud.

Gene Therapy Program \| University of Pennsylvania Email Formats	Example	Percentage
FLast@upenn.edu	JDoe@upenn.edu	67%
FirstL@upenn.edu	JohnD@upenn.edu	6%
Last@upenn.edu	Doe@upenn.edu	4%
LastF@upenn.edu	DoeJ@upenn.edu	4%
First.Last@upenn.edu	John.Doe@upenn.edu	3%
First@upenn.edu	John@upenn.edu	3%
LastFirst@upenn.edu	DoeJohn@upenn.edu	2%
LFirst@upenn.edu	DJohn@upenn.edu	2%
FiLast@upenn.edu	JoDoe@upenn.edu	1%
FirstLa@upenn.edu	JohnDo@upenn.edu	2%
FirstLast@upenn.edu	JohnDoe@upenn.edu	1%
FirLast@upenn.edu	JohDoe@upenn.edu	1%
LastFi@upenn.edu	DoeJo@upenn.edu	1%
FirstLas@upenn.edu	JohnDoe@upenn.edu	1%
LF@upenn.edu	DJ@upenn.edu	1%
Middle@upenn.edu	Michael@upenn.edu	1%

Gene Therapy Program | University of Pennsylvania

Q: When was Gene Therapy Program | University of Pennsylvania founded?

Gene Therapy Program | University of Pennsylvania was founded in 1993.

Biotechnology ResearchPennsylvania, United States11-50 Employees

Dedicated to discovery + translational research and led by Dr. James Wilson, the Gene Therapy Program (GTP) at the University of Pennsylvania focuses on the development of next-generation gene transfer vectors and their application in the treatment of a variety of acquired and inherited diseases. 

Dr. Wilson's commitment to patients with rare diseases stems from his days as a graduate student and medical student at the University of Michigan between 1977 and 1984. He was discouraged by the lack of available treatments for rare disease patients, but optimistic that science could yield solutions with his initial focus being gene therapy. He completed his training in Internal Medicine at the Massachusetts General Hospital followed by a postdoctoral fellowship at the Whitehead Institute where he began his work in gene therapy.

After launching his faculty career in the Howard Hughes Medical Institute and the University of Michigan, he moved to the University of Pennsylvania in 1993. Jim’s laboratory has made seminal contributions to the technology of gene transfer and has paved the way for translation of these technologies into the clinic. He has published more than 550 papers and is named on more than 110 patents.

Today, the goals of the Gene Therapy Program are to develop and commercialize transformative, genetic-based therapeutics. These goals are driven by the unmet needs of patients with inherited genetic diseases.

The Gene Therapy Program currently employs more than 350+ full-time employees with an annual operating budget based on funding from a diverse group of public and private sponsors.

Insights

Similar companies to Gene Therapy Program | University of Pennsylvania

Orchard Therapeutics - U.S.

AVROBIO

GenSight Biologics

Editas Medicine

uniQure

bluebird bio

Oxford Biomedica